63.58
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Is Soleno Therapeutics Inc. building a consolidation baseGold Moves & Technical Pattern Recognition Alerts - newser.com
Soleno Therapeutics Appoints Mark W. Hahn to Board and Audit Committee - TradingView
How to recover losses in Soleno Therapeutics Inc. stockJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com
Strategies to average down on Soleno Therapeutics Inc.2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Will Soleno Therapeutics Inc. outperform the market2025 Price Action Summary & Reliable Price Breakout Alerts - newser.com
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationSLNO - PR Newswire
Soleno Therapeutics appoints biopharma finance veteran to board By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - WV News
Using Bollinger Bands to evaluate Soleno Therapeutics Inc.2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Has Soleno Therapeutics Inc. formed a bullish divergenceJuly 2025 Highlights & Fast Entry High Yield Tips - newser.com
Is Soleno Therapeutics Inc. stock entering bullish territoryPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
Multi asset correlation models including Soleno Therapeutics Inc.July 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Soleno Therapeutics appoints biopharma finance veteran to board - Investing.com India
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors - GlobeNewswire
Soleno Therapeutics, Inc. Appoints Mark W. Hahn as an Independent Director to Its Board of Directors and A Member of Its Audit Committee - MarketScreener
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring an 86% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
SLNO Investor News: If You Have Suffered Losses in Soleno - GlobeNewswire
Soleno drops on death of patient treated with Vykat XR - MSN
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Soleno Therapeutics (SLNO): Valuation in Focus After Scorpion Capital Report and Legal Probes on VYKAT XR - Sahm
Soleno Stock: Blockbuster Launch In Progress (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
How to use Fibonacci retracement on Soleno Therapeutics Inc.Gap Down & Fast Moving Stock Watchlists - newser.com
Published on: 2025-10-10 05:36:53 - newser.com
Can Soleno Therapeutics Inc. stock deliver sustainable ROEMarket Volume Report & Expert Curated Trade Setup Alerts - newser.com
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
Published on: 2025-10-09 06:36:22 - newser.com
Will Soleno Therapeutics Inc. bounce back from current supportJuly 2025 Gainers & Capital Protection Trading Alerts - newser.com
What Wall Street predicts for Soleno Therapeutics Inc. stock priceAnalyst Downgrade & Weekly High Return Stock Forecasts - newser.com
Soleno Therapeutics (NASDAQ:SLNO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Is Soleno Therapeutics Inc 6XC a good long term investment - earlytimes.in
Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT - Yahoo Finance
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 7%Should You Buy? - MarketBeat
Soleno Therapeutics (SLNO): Reassessing Valuation After VYKAT XR Safety Debate and Analyst Support - Yahoo Finance
Goldman Sachs Initiates Soleno Therapeutics at Buy With $125 Price Target - MarketScreener
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Goldman Sachs initiates Soleno Therapeutics stock with Buy rating on Vykat potential - Investing.com
Is Soleno Therapeutics Inc. stock supported by strong cash flows - newser.com
Soleno Therapeutics (SLNO) Is Down 8.9% After Short Seller Targets VYKAT XR Safety and Market Potential – Has The Bull Case Changed? - Sahm
How Soleno Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Detecting support and resistance levels for Soleno Therapeutics Inc.Weekly Stock Recap & Verified Entry Point Signals - newser.com
How Soleno Therapeutics Inc. (6XC) stock stacks up against competitorsMarket Performance Summary & Growth Focused Entry Reports - newser.com
Soleno Therapeutics (SLNO): Assessing Valuation and Growth Potential in the Biotech Sector - Sahm
Piper Sandler reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):